Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Pre-Market Trading 11-22 08:19:42 EST

2.11

+0.07

+3.43%

盘前2.18

+0.07+3.28%

08:17 EST

High2.23	Low2.03	Vol478.92K
Open2.03	D1 Closing2.04	Amplitude9.80%
Mkt Cap62.57M	Tradable Cap44.30M	Total Shares29.65M
T/O1.02M	T/O Rate2.28%	Tradable Shares20.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":2.11,"timestamp":1732222800000,"preClose":2.04,"halted":0,"volume":478916,"hourTrading":{"tag":"盘前","latestPrice":2.1792,"preClose":2.11,"latestTime":"08:17 EST","volume":1668,"amount":3623.0983284000004,"timestamp":1732281455414},"delay":0,"floatShares":20992947,"shares":29653355,"eps":-1.965974,"marketStatus":"Pre-Market Trading","change":0.07,"latestTime":"11-22 08:19:42 EST","open":2.03,"high":2.23,"low":2.03,"amount":1024297.6386860001,"amplitude":0.098039,"askPrice":2.18,"askSize":917,"bidPrice":2.12,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.965974,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":2.11,"preHourTrading":{"tag":"盘前","latestPrice":2.1792,"preClose":2.11,"latestTime":"08:17 EST","volume":1668,"amount":3623.0983284000004,"timestamp":1732281455414},"postHourTrading":{"tag":"盘后","latestPrice":2.1018,"preClose":2.11,"latestTime":"19:58 EST","volume":803,"amount":1694.483,"timestamp":1732237088171},"volumeRatio":0.8633784029269973},"requestUrl":"/m/hq/s/IMRX/wiki","defaultTab":"wiki","newsList":[{"id":"2483876123","title":"Cautious Hold Recommendation on Immuneering Amid Promising Developments and Financial Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876123?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:57","pubTimestamp":1731585451,"startTime":"0","endTime":"0","summary":"Immuneering (IMRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeffrey Hung from Mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-hold-recommendation-on-immuneering-amid-promising-developments-and-financial-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-hold-recommendation-on-immuneering-amid-promising-developments-and-financial-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","IMRX","BK4139","BK4539"],"gpt_icon":0},{"id":"2483824216","title":"Immuneering Price Target Maintained With a $15.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2483824216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483824216?lang=en_us&edition=fundamental","pubTime":"2024-11-14 18:31","pubTimestamp":1731580260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 05:31 ET (10:31 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2483212118","title":"Immuneering’s Promising Outlook: Strong Clinical Progress and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2483212118","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483212118?lang=en_us&edition=fundamental","pubTime":"2024-11-14 18:16","pubTimestamp":1731579406,"startTime":"0","endTime":"0","summary":"Ami Fadia, an analyst from Needham, maintained the Buy rating on Immuneering (IMRX – Research Report). The associated price target remains the same...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immuneerings-promising-outlook-strong-clinical-progress-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immuneerings-promising-outlook-strong-clinical-progress-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","IMRX","BK4097","BK4563","PRGS","LU2065732104.USD"],"gpt_icon":0},{"id":"2483865849","title":"Immuneering reports Q3 EPS (49c), consensus (55c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483865849","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483865849?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:30","pubTimestamp":1731533426,"startTime":"0","endTime":"0","summary":"Reports Q3 cash, cash equivalents and marketable securities as of September 30 were $50.7M , compared with $85.7M as of December 31, 2023. The Sept...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-reports-q3-eps-49c-consensus-55c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-reports-q3-eps-49c-consensus-55c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX"],"gpt_icon":0},{"id":"2483868102","title":"Immuneering Q3 2024 GAAP EPS $(0.49) Beats $(0.56) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868102","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868102?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:10","pubTimestamp":1731532211,"startTime":"0","endTime":"0","summary":"Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.56) by 12.5 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41954328/immuneering-q3-2024-gaap-eps-0-49-beats-0-56-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immuneering Q3 2024 GAAP EPS $(0.49) Beats $(0.56) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2483863431","title":"Immuneering Corp: Cash Runway Into Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863431?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA1YBXZ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","IMRX","BK4563"],"gpt_icon":0},{"id":"2483868596","title":"Immuneering Corporation Q3 Net Income USD -14.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868596?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLXAD4FBE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4539","IMRX","BK4139"],"gpt_icon":0},{"id":"2483868598","title":"Immuneering Corporation Q3 EPS USD -0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868598","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868598?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLXAD4FBE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4539","IMRX","BK4139"],"gpt_icon":0},{"id":"2476945329","title":"IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2476945329","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476945329?lang=en_us&edition=fundamental","pubTime":"2024-10-16 22:24","pubTimestamp":1729088640,"startTime":"0","endTime":"0","summary":"Immuneering Corporation IMRX announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up 15.5% on Oct. 15 following the announcement of the news.The FDA grants Orphan Drug Designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The Orphan Drug Designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies as well as exemptions from certain FDA application fees.IMM-1-104 was earlier granted the FDA’s Fast Track designation in the United States for the treatment of first- and second-line pancreatic cancer.Year to date, shares of Immuneering have plunged 68.6% compared with the industry’s decrease of 1.8%.Last month, the company announced positive early response data from the first five patients of an ongoin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imrx-stock-fdas-orphan-drug-142400084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMRX","ALNY","BK4539","BK4585","BK4563","BK4588","BK4548","BK4007","VYGR","ANIP","BK4139"],"gpt_icon":0},{"id":"2475330500","title":"Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2475330500","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475330500?lang=en_us&edition=fundamental","pubTime":"2024-10-15 21:16","pubTimestamp":1728998166,"startTime":"0","endTime":"0","summary":"Immuneering  said Tuesday that its investigational drug IMM-1-104 has received orphan drug designation from the US Food and Drug Administration in the treatment of pancreatic cancer.The company said a phase 2a clinical trial to evaluate IMM-1-104 combined with chemotherapy in patients with advanced solid tumors, including pancreatic cancer, is ongoing.The company, which recently announced positive initial phase 2a results, said it expects to provide initial data from at least one additional arm of the phase 2a portion of its phase 1/2a trial before the end of the year.Shares of Immuneering advanced 23% in premarket activity Tuesday.Price: 2.4600, Change: +0.46, Percent Change: +23.00","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","IMRX","BK4563"],"gpt_icon":0},{"id":"2475450738","title":"Immuneering rises on orphan drug designation for treatment of pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2475450738","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475450738?lang=en_us&edition=fundamental","pubTime":"2024-10-15 21:04","pubTimestamp":1728997456,"startTime":"0","endTime":"0","summary":"koto_feja  Immuneering Corporation (NASDAQ:IMRX) shares up 24.5% premarket after it announced that the U.S. FDA has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1623196413/image_1623196413.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1623196413/image_1623196413.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4159870-immuneering-rises-on-orphan-drug-designation-for-treatment-of-pancreatic-cancer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4585","MNQmain","TQQQ","BK4584","IMRX","BK4588","BK4007","NQmain","BK4559",".IXIC","BK4139","QLD","QID","BK4566","TEVA","BK4539","PSQ","BK4557","BK4563","SQQQ"],"gpt_icon":0},{"id":"2475506338","title":"Immuneering granted Orphan Drug Designation for IMM-1-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2475506338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475506338?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:21","pubTimestamp":1728994864,"startTime":"0","endTime":"0","summary":"Immuneering announced that the U.S. Food and Drug Administration has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic ca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-granted-orphan-drug-designation-for-imm-1-104?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-granted-orphan-drug-designation-for-imm-1-104?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4563","IMRX"],"gpt_icon":0},{"id":"2475508925","title":"Immuneering Granted Orphan Drug Designation for Imm-1-104 by FDA in the Treatment of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2475508925","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475508925?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:00","pubTimestamp":1728993601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nTUA5RKBSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","IMRX","BK4563"],"gpt_icon":0},{"id":"2475150820","title":"Immuneering Corp: Imm-1-104 Is Currently Being Evaluated in a Phase 2a Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2475150820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475150820?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:00","pubTimestamp":1728993601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nTUA5RKBSG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4563","BK4139","BK4539"],"gpt_icon":0},{"id":"2475038565","title":"Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2475038565","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475038565?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:00","pubTimestamp":1728993600,"startTime":"0","endTime":"0","summary":"- Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients - -I","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/15/2963129/0/en/Immuneering-Granted-Orphan-Drug-Designation-for-IMM-1-104-by-FDA-in-the-Treatment-of-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4539","BK4563"],"gpt_icon":0},{"id":"2475670873","title":"Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2475670873","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475670873?lang=en_us&edition=fundamental","pubTime":"2024-10-14 21:26","pubTimestamp":1728912361,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So, the natural question for Immuneering  shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.How Is Immuneering's Cash Burn Changing Over Time?Since it has a market capitalisation of US$65m, Immuneering's US$51m in cash burn equates to about 79% of its market value. That's very high expenditure rela","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-bit-worried-132601193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","IE00B3QW5Z07.USD","QLD","LU2210150020.SGD","BK4588","QID","LU2210149790.SGD","PSQ","SQQQ","IE00BGHQF748.EUR","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585",".IXIC","BK4139","LU2095319765.USD","MNQmain","TQQQ","IMRX","NQmain","BK4112","BK4539"],"gpt_icon":1},{"id":"2474407112","title":"Immuneering treatment of pancreatic cancer granted FDA orphan status","url":"https://stock-news.laohu8.com/highlight/detail?id=2474407112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474407112?lang=en_us&edition=fundamental","pubTime":"2024-10-09 03:00","pubTimestamp":1728414022,"startTime":"0","endTime":"0","summary":"Immuneering’s treatment of pancreatic cancer was granted FDA orphan designation, according to a post to the agency’s website. Published first on Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-treatment-of-pancreatic-cancer-granted-fda-orphan-status?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-treatment-of-pancreatic-cancer-granted-fda-orphan-status?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4563","IMRX"],"gpt_icon":0},{"id":"2469903971","title":"Wall Street Breakfast: The Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2469903971","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469903971?lang=en_us&edition=fundamental","pubTime":"2024-09-22 19:35","pubTimestamp":1727004958,"startTime":"0","endTime":"0","summary":"Here are the most attractive high-yield dividend stocks right now‘No pain, no gain,’ just look at stocks that jumped at least 900% in a 5-year time spanHow four election outcomes could impact the marketsSmall-cap stocks have climbed recently. Here are the ones best positioned for further upsideJamie Dimon: Geopolitical","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1490939019/image_1490939019.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1490939019/image_1490939019.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4722549-wall-street-breakfast-week-ahead","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0943347566.SGD","LU0289739343.SGD","SFIX","JBL","US30Y.BOND","US912797GW17.BOND","US3Y.BOND","LU0965509101.SGD","LU1496350502.SGD","US912797HE00.BOND","ALXO","SGXZ31699556.SGD","LGCY","LU0719512351.SGD","US6M.BOND","BKV","AZO","BK4561","SG9999018857.SGD","GRDN","BK4512","US2Y.BOND","MU","ETON","LU0175139822.USD","US10Y.BOND","BK4139","JEF","TURB","US12M.BOND","LU0323240290.USD","US7Y.BOND","BMRN","BK4585","IMRX","KBH","KMX","ACN","LU1934455194.USD","US5Y.BOND","PGHL","IE0002270589.USD","VERV","IART","COST","AZUL","THO","LU2247934214.USD","BIRK"],"gpt_icon":1},{"id":"2469047670","title":"Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers","url":"https://stock-news.laohu8.com/highlight/detail?id=2469047670","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469047670?lang=en_us&edition=fundamental","pubTime":"2024-09-21 03:00","pubTimestamp":1726858855,"startTime":"0","endTime":"0","summary":"Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Seeking Alpha's earnings calendar for a full list of companies due to report.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/888867856/image_888867856.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/888867856/image_888867856.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4151613-catalyst-watch-spotlight-on-micron-southwest-airlines-and-fomc-speakers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["US12M.BOND","BMRN","SFIX","LUV","JEF","KBH","BBU","AZO","GIS","BRZE","INTU","MPAA","US10Y.BOND","MU","MRK","SNY","AZUL","VERV","NBIX","ETON","VSTO","SMP","NXST","WCC","KMX","US5Y.BOND","FOMC","US6M.BOND","ALXO","JBL","US7Y.BOND","MGM","BIRK","ACN","IMRX","ENV","AAN","BMY","HOV","J","WSC","ZETA","PGHL","US30Y.BOND"],"gpt_icon":1},{"id":"2468503214","title":"Immunotherapy Clinical Trials - A New Approach to Treating Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2468503214","media":"Newsfile","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468503214?lang=en_us&edition=fundamental","pubTime":"2024-09-19 22:00","pubTimestamp":1726754400,"startTime":"0","endTime":"0","summary":"Vancouver, Kelowna, and Delta, British Columbia-- - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, featuring Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections. Aethlon's Hemopurifier is a clinical stage immunotherapeutic device designed to combat cancer.Following the news of cancer trials activated in Australia earlier this week, Aethlon Medical, Inc.  today announced that, on September 9, 2024, the Medanta Institutional Ethics Committee  granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Merck & Co., Inc.'s Keytruda (pembrolizum","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UdPYizQKrbmf.swyqvN2IA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/c6a4a4a3b84eef073f2061b8f1941e81","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UdPYizQKrbmf.swyqvN2IA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/c6a4a4a3b84eef073f2061b8f1941e81"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/immunotherapy-clinical-trials-approach-treating-140000188.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunotherapy-clinical-trials-approach-treating-140000188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","LU2264538146.SGD","BK4187","BK4532","AEMD","BK4564","BK4583","BK4505","BK4588","BK4082","LU1064131342.USD","LU1988902786.USD","BK4139","BK4516","BK4585","IMRX","NOC"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":0.0876},{"period":"1month","weight":-0.0409},{"period":"3month","weight":0.972},{"period":"6month","weight":0.518},{"period":"1year","weight":-0.7172},{"period":"ytd","weight":-0.7129}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.239671},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.009906},{"month":3,"riseRate":0.333333,"avgChangeRate":0.105982},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.203232},{"month":5,"riseRate":0,"avgChangeRate":-0.137963},{"month":6,"riseRate":0.666667,"avgChangeRate":0.145613},{"month":7,"riseRate":0.666667,"avgChangeRate":0.029987},{"month":8,"riseRate":0.25,"avgChangeRate":0.029018},{"month":9,"riseRate":0.75,"avgChangeRate":0.686735},{"month":10,"riseRate":0.25,"avgChangeRate":-0.087438},{"month":11,"riseRate":0.25,"avgChangeRate":-0.1572},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.139244}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}